Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 1421

1.

Depression and clinical progression in HIV-infected drug users treated with highly active antiretroviral therapy.

Bouhnik AD, Préau M, Vincent E, Carrieri MP, Gallais H, Lepeu G, Gastaut JA, Moatti JP, Spire B; MANIF 2000 Study Group.

Antivir Ther. 2005;10(1):53-61.

PMID:
15751763
2.
3.

Determinants of HIV progression and assessment of the optimal time to initiate highly active antiretroviral therapy: PISCIS Cohort (Spain).

Jaén A, Esteve A, Miró JM, Tural C, Montoliu A, Ferrer E, Riera M, Segura F, Force L, Sued O, Vilaró J, Garcia I, Masabeu A, Altès J, Coltet B, Podzamczer D, Murillas J, Navarro G, Gatell JM, Casabona J; PISCIS Study Group.

J Acquir Immune Defic Syndr. 2008 Feb 1;47(2):212-20.

PMID:
18297762
4.

The effect of depressive symptoms at ART initiation on HIV clinical progression and mortality: implications in clinical practice.

Villes V, Spire B, Lewden C, Perronne C, Besnier JM, Garré M, Chêne G, Leport C, Carrieri MP, Le Moings V; ANRS CO-8 APROCO-COPILOTE Study Group.

Antivir Ther. 2007;12(7):1067-74.

PMID:
18018765
6.
7.

The impact of adherence on CD4 cell count responses among HIV-infected patients.

Wood E, Hogg RS, Yip B, Harrigan PR, O'Shaughnessy MV, Montaner JS.

J Acquir Immune Defic Syndr. 2004 Mar 1;35(3):261-8.

PMID:
15076240
8.
9.

Determinants of clinical progression in antiretroviral-naive HIV-infected patients starting highly active antiretroviral therapy. Aquitaine Cohort, France, 1996-2002.

Bonnet F, Thiébaut R, Chêne G, Neau D, Pellegrin JL, Mercié P, Beylot J, Dabis F, Salamon R, Morlat P; Groupe d'Epidemiologie Clinique du SIDA en Aquitaine (GECSA).

HIV Med. 2005 May;6(3):198-205.

10.
11.

Role of hepatitis C virus (HCV) viremia and HCV genotype in the immune recovery from highly active antiretroviral therapy in a cohort of antiretroviral-naive HIV-infected individuals.

Antonucci G, Girardi E, Cozzi-Lepri A, Capobianchi MR, De Luca A, Puoti M, Petrelli E, Carnevale G, Rizzardini G, Grossi PA, Viganò P, Moioli MC, Carletti F, Solmone M, Ippolito G, Monforte AD; HepaI.Co.N.A. Study Group; Italian Cohort Naive for Antiretrovirals Study Group.

Clin Infect Dis. 2005 Jun 15;40(12):e101-9. Epub 2005 May 5.

12.

A comparison of exposure groups in the EuroSIDA study: starting highly active antiretroviral therapy (HAART), response to HAART, and survival.

Mocroft A, Madge S, Johnson AM, Lazzarin A, Clumeck N, Goebel FD, Viard JP, Gatell J, Blaxhult A, Lundgren JD.

J Acquir Immune Defic Syndr. 1999 Dec 1;22(4):369-78.

PMID:
10634199
13.

Virological control during the first 6-18 months after initiating highly active antiretroviral therapy as a predictor for outcome in HIV-infected patients: a Danish, population-based, 6-year follow-up study.

Lohse N, Kronborg G, Gerstoft J, Larsen CS, Pedersen G, Pedersen C, Sørensen HT, Obel N.

Clin Infect Dis. 2006 Jan 1;42(1):136-44. Epub 2005 Nov 30.

14.

Effects of depression and selective serotonin reuptake inhibitor use on adherence to highly active antiretroviral therapy and on clinical outcomes in HIV-infected patients.

Horberg MA, Silverberg MJ, Hurley LB, Towner WJ, Klein DB, Bersoff-Matcha S, Weinberg WG, Antoniskis D, Mogyoros M, Dodge WT, Dobrinich R, Quesenberry CP, Kovach DA.

J Acquir Immune Defic Syndr. 2008 Mar 1;47(3):384-90.

PMID:
18091609
15.

Mortality in HIV-seropositive versus -seronegative persons in the era of highly active antiretroviral therapy: implications for when to initiate therapy.

Wang C, Vlahov D, Galai N, Bareta J, Strathdee SA, Nelson KE, Sterling TR.

J Infect Dis. 2004 Sep 15;190(6):1046-54. Epub 2004 Aug 17.

16.

Are there gender differences in starting protease inhibitors, HAART, and disease progression despite equal access to care?

Mocroft A, Gill MJ, Davidson W, Phillips AN.

J Acquir Immune Defic Syndr. 2000 Aug 15;24(5):475-82.

PMID:
11035619
17.

Impact of HAART-related side effects on unsafe sexual behaviours in HIV-infected injecting drug users: 7-year follow up.

Vincent E, Bouhnik AD, Carrieri MP, Rey D, Dujardin P, Granier F, Fuzibet JG, Obadia Y, Moatti JP, Spire B; MANIF-2000 Study Group.

AIDS. 2004 Jun 18;18(9):1321-5.

PMID:
15362665
18.
19.

Predictors of clinical progression among HIV-1-positive patients starting HAART with CD4+ T-cell counts > or =200 cells/mm3.

Lapadula G, Torti C, Maggiolo F, Casari S, Suter F, Minoli L, Pezzoli C, Di Pietro M, Migliorino G, Ouiros-Roldan E, Ladisa N, Sighinolfi L, Costarelli S, Carosi G; Italian MASTER Cohort.

Antivir Ther. 2007;12(6):941-7.

PMID:
17926648
20.

Psychosocial determinants of adherence to highly active antiretroviral therapy among injection drug users in Vancouver.

Kerr T, Palepu A, Barness G, Walsh J, Hogg R, Montaner J, Tyndall M, Wood E.

Antivir Ther. 2004 Jun;9(3):407-14.

PMID:
15259903
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk